Objective Soft tissue sarcoma (STS) originating from the non-extremities has a poor prognosis and risk for visceral crisis; therefore, combination chemotherapy with a high response rate is desired. Methods We retrospectively reviewed the cases of 30 patients with advanced STS that originated from the non-extremities who were treated between October 2005 and February 2012 at our institute with the CYVADIC chemotherapy regimen, which consists of cyclophosphamide, vincristine, doxorubicin, and dacarbazine. The patients' objective responses, progression-free survival (PFS), and overall survival (OS) were evaluated, and a statistical analysis was conducted to identify the predictive factors related to response and survival. Results The median follow-up time was 16.5 months. The response rate was 33%, the median PFS was 7.4 months, and the 1-year OS was 81% (the OS did not reach the median). The median number of treatment cycles was six. Eleven patients failed to complete 6 cycles due to disease progression. The number of involved organs (>3) was a significant predictive factor of early refractoriness by the logistic regression analysis. Thirteen patients had an objective response or PFS longer than 1 year, and an alkaline phosphatase (ALP) level within the normal limits were the significant predictive factors of a good response. Conclusion The patients' responses to the CYVADIC therapy for advanced STS originating from the nonextremities were moderate; therefore, CYVADIC therapy may be a treatment option of choice as combination chemotherapy for such patients. We propose that the number of involved organs and ALP concentration may be useful measures to predict the response to the CYVADIC therapy.
liver, gastrointestinal tract, and kidneys), leading to organ dysfunction and affecting the patient's performance status and prognosis. To reduce the risk of such serious organ dysfunction due to STS, chemotherapy regimens with high response rates are needed.
CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) therapy is a combination chemotherapy regimen that has been used to treat STS patients. This regimen is known to have a relatively high response rate, though it has not been shown to be superior to doxorubicin single-agent chemotherapy for overall survival in a randomized study (4, 5) . In Japan, however, there have been many case reports of patients highly responsive to the CYVADIC regimen, especially patients with STSs that originated from the non-extremities (6) (7) (8) (9) . In light of its apparent high response rate and positive case reports, the CYVADIC regimen's clinical benefits for STS originating from the nonextremities should be determined. In the present retrospective study, we herein examined 30 patients with STS that originated from a non-extremity site who were treated with the CYVADIC regimen in Japan.
Materials and Methods
We retrospectively reviewed the cases of advanced or relapsed patients with STSs that originated from a nonextremity site and were treated with CYVADIC therapy between October 2005 and February 2012 at the Department of Medical Oncology in our institute. All patients had undergone a biopsy and were diagnosed pathologically. All of the pathological diagnoses, including 22 consulted cases, were reviewed by a well-trained pathologist in our institution.
The CYVADIC regimen administered to each patient consisted of cyclophosphamide (d2, 500 mg/m 2 ), vincristine (d1, 1.5 mg/m 2 , max 2.0 mg/body), doxorubicin (d1, 50 mg/m 2 ), and dacarbazine (d1-5, 250 mg/m 2 ). One cycle lasted 28 days. The CYVADIC therapy was continued until the patient exhibited progressive disease (PD), completed 6 cycles, or developed an intolerable adverse event. After the completion of 6 cycles of the CYVADIC therapy without disease progression, additional locoregional therapy, palliative therapies, or continuation of the CYVADIC regimen were performed if appropriate. In cases in which the CYVADIC therapy was continued for more than 6 cycles, the doxorubicin was discontinued when the cumulative dose of doxorubicin reached 450 mg/m 2 . For measurable disease, objective responses were evaluated using computed tomography (CT) and magnetic resonance imaging (MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The U.S. National Center Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0) were used to evaluate toxicity. Using the Kaplan-Meier method, we calculated the progression-free survival (PFS) and overall survival (OS) of each patient from the start of the CYVADIC regimen to disease progression and death, respectively. Patients with an objective response or PFS longer than 1 year were defined as "good responders," while patients who failed to complete all 6 cycles of the CYVADIC therapy because of progression were the "early refractory" patients. A logistic regression analysis was used for the predictive factors of good responders and early refractory. In all of the analyses, a p< 0.05 was considered to be statistically significant.
This retrospective study was approved by the Institutional Review Board.
Results

Patient characteristics
Between October 2005 and February 2012, a total of 30 patients with STS were treated with the CYVADIC therapy. The characteristics of these patients at the induction of the CYVADIC therapy are summarized in Table 1 . The median age was 48 years old (range: 21-74), and all patients had good performance statuses (ECOG 0 or 1). Seven patients had only 1 organ involved, but 8 patients (27%) had 4 or more lesions, and 16 patients (53%) had a bulky mass.
The pathological diagnoses are shown in Table 2 . Pathological specimens were obtained by a needle biopsy in 9 patients (including 5 specimens borrowed and reviewed for consultation) or by an incision biopsy in 21 patients (including 17 specimens borrowed and reviewed for consultation). Regarding the morphological features of the specimens, 19 patients (63%) had spindle cell sarcomas including 6 leiomyosarcomas, 2 synovial sarcomas, 1 dedifferentiated liposarcoma, 1 malignant solitary fibrous tumor, and 1 angiosarcoma; in another 8 cases, the pathological diagnoses were not clear due to limitations of the borrowed specimens. Seven patients (23%) had pleomorphic sarcomas including 2 dedifferentiated liposarcomas and 2 malignant fibrous histiocytomas (MFH)/undifferentiated pleomorphic sarcoma (UPS); the pathological diagnoses of the other 3 patients were unclear due to the limitations of the borrowed specimens. Two patients (7%) had myxoid sarcomas, myxoid liposarcoma and myxofibroliposarcoma. The other 2 patients had neuroblastoma and sarcoma with rhabdoid features, respectively. The most prevalent pathological diagnosis was leiomyosarcoma (6 patients, 20%), followed by liposarcoma (4 patients, 13%), synovial sarcoma (2 patients, 7%), and MFH/UPS (2 patients, 7%).
In the laboratory data, severe myelosuppression was not seen at the induction of the CYVADIC therapy, but 10 patients (33%) had low lymphocyte counts (less than 1,000/ mm 3 ). A high lactate dehydrogenase (LDH) level was seen in 14 patients (47%), and a high alkaline phosphatase (ALP) concentration was seen in 13 patients (43%).
Nineteen patients (63%) had received one or more prior therapies; 17 patients received surgical therapy, 6 patients received radiation therapy, and 1 patient received chemotherapy (a combination of ifosfamide, carboplatin, and 
etoposide) before the CYVADIC therapy.
Efficacy
The median follow-up time was 16.5 months. At the time of analysis, disease progression was seen in 23 patients following the induction of CYVADIC therapy, and 13 patients died of disease. The median number of treatment cycles of the CYVADIC therapy was six.
The objective response rate was 33% [partial response (PR) 23%, complete response (CR) 10%]. The response rates were not significantly different between the patient groups categorized by the morphological features or pathological diagnoses ( Table 2 ). The 1-year OS rate was 81%, and the 1-year PFS rate was 37%. The median PFS period was 7.4 months (Fig. 1) . The presence of previous treatment was not significant for the OS (p=0.373) or the PFS (p= 0.827).
Thirteen patients had an objective response or PFS longer than 1 year (i.e., they were "good responders"). In contrast, 11 patients failed to complete all 6 cycles of the CYVADIC therapy due to disease progression (i.e., they were the "early refractory" patients). The predictive factors for a "good responder" or an "early refractory" patient were explored. In a logistic regression analysis, "4 or more organs invaded" was a significant predictive factor of early refractory in patients (p=0.019, OR=9.60, 95% CI: 1.45-63.50, Table 3) , and an ALP level within the normal limits was found to be a significant predictive factor of good responders (p=0.032, OR= 7.14, 95% CI: 1.18-43.48, Table 4 ). These factors, however, did not correlate with the PFS or OS (Fig. 2) .
Adverse events
Grade 3 or 4 hematologic adverse events were seen in 24 patients (80%), and grade 3 or 4 nonhematologic adverse events were seen in 4 patients (13%) ( Table 5 ). Cardiological adverse events were not observed. Furthermore, no patients expired or discontinued the CYVADIC regimen due to an adverse event, but 5 patients required dose modification due to adverse events; myelosuppression (2 patients), renal dysfunction (1 patient), and paralytic ileus (2 patients) were the reasons for the dose reductions.
Discussion
Combination chemotherapy regimens for advanced STS patients have not been demonstrated to be superior to singleagent chemotherapy in terms of the OS until now, although such regimens have shown relatively high response rates. In particular circumstances, however, combination chemotherapy may be beneficial and the treatment of choice, especially when a tumor response may give an advantage and the patient's performance status is good (1, 2) . STSs originating from the non-extremities are similar to those originating from extremities with respect to pathological features. However, these two conditions differ in the distribution of metastatic lesions; STS originating from the non-extremities have a relatively low risk of lung metastasis, but high risk of visceral metastases other than lung, which include liver, bone, or gastrointestinal tracts (10) . The difference in the type of metastatic lesions could suggest that patients with STS originating from the non-extremities have a higher risk of organ dysfunctions, such as pleural effusion from the diaphragm or mediastinal invasion, renal dysfunction, or obstructive jaundice from abdominal lesions. In fact, in a retrospective analysis of 2,136 STS patients treated with surgical resection at the Memorial Sloan-Kettering Cancer Center in New York, "non-extremity origin" was one of the factors for a poor prognosis (11).
Karavasilis et al. reported the treatment and prognosis of 488 advanced and/or metastatic STS patients in a retrospective study (3) . In this study, 61% of the patients received single-agent chemotherapy and 39% received combination chemotherapy; patients who received the combination chemotherapy had a higher objective response rate (47% vs. 25%, p<0.001) and longer OS (16 months vs. 11 months; Leukocytopenia  30  100  13  43  8  27  Neutropenia  29  97  3  10  18  60  Anemia  24  80  4  13  0  0  Thrombocytopenia  7  23  0  0  2  7  Non-hematologic adverse events  Nausea  27  90  0  0  0  0  Vomiting  27  90  0  0  0  0  Diarrhea  5  17  0  0  0  0  Constipation  10  33  2  7  0  0  Infection  6  20  1  3  0  0  Phlebitis  12 RR=1.40, 95% CI: 1.12-1.74, p=0.003). Distribution of the primary site of disease was not shown; however, symptoms at the metastatic disease were seen in 49% of the patients.
Patients with STS of a non-extremity origin are often exposed to a high risk of organ dysfunction, so combination chemotherapy with a good response rate could be beneficial. The most frequently used combination regimen in Karavasilis' study is ifosfamide and doxorubicin, but this combination has some disadvantages for patients with STS of a nonextremity origin: high-volume hydration (2-3 L/day) and concomitant use of mesna are necessary for the infusion of high-dose ifosfamide treatment; the dose of doxorubicin used is almost the same as that for its use in single-agent doxorubicin therapy; and the risk of cardiological toxicity is not reduced. The CYVADIC regimen is a combination chemotherapy regimen consisting of cyclophosphamide, vincristine, doxorubicin, and dacarbazine. Yap et al. reported the response rate and prognoses of 140 adult patients with advanced sarcomas treated with the CYVADIC therapy: the response rate was 47% (15% complete); the median duration of response was 9.5 months for complete responders and 7 months for partial responders; and the median survival time was 16 months for responders and 7 months for nonresponders (12) . The CYVADIC therapy only requires a relatively low-volume infusion and lower doses of doxorubicin; therefore, it would be a less invasive and safer combination regimen.
In a randomized Phase III study by the European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group, three arms of treatment regimens for advanced STSs were compared (4): doxorubicin 75 mg/m 2 (arm A), CYVADIC (arm B), and ifosfamide 5 g/m 2 plus doxorubicin 50 mg/m 2 (arm C). The randomized study showed no significant differences among the three study arms in terms of response rate (arm A, 23.3%; arm B, 28.4%; and arm C, 28.1%) or in the duration of remission (median, 46 weeks in arm A, 48 weeks in arm B, and 44 weeks in arm C) (4) . In that study, however, the percentage of STSs originating from the non-extremities was not de-scribed. Patients included in the study had a high rate of lung metastasis (52.2%), but a low rate of liver (18.6%), bone (13.7%), or other visceral lesions (7.1%) that did not reflect the STSs originating from the non-extremities. Thus, for patients with STS originating from the non-extremities, who have different distributions of metastases and high risks of organ dysfunction, the benefits of the CYVADIC regimen should be evaluated.
In the prior retrospective analyses of STS outcomes, other than "non-extremity origin" as a factor, the patient's performance status, old age, low lymphocyte count in the peripheral blood, and bulky mass were identified as poorprognosis factors (13, 14) . In our present study, all patients had performance statuses high enough to endure the CYVADIC therapy, but a high number of patients had the risk factors of lymphocytopenia (33%) or bulky mass (53%). The patients who had these risk factors responded to the CYVADIC therapy as well as the patients in previous clinical trials, and these factors were not indicative of a significant risk for early refractory. In addition, the adverse events following the CYVADIC therapy were tolerable, and cardiological adverse events did not occur. Therefore, the CYVADIC regimen may be a beneficial treatment option for patients with multiple risk factors.
In our study, the number of organs invaded and ALP level were associated with response to the CYVADIC therapy in a logistic regression analysis, but they were not predictive factors of prognosis. If we consider combination chemotherapy treatment for advanced STS patients, however, a higher response rate is necessary. These predictive factors may be useful for selecting a particular treatment regimen out of the possible combination chemotherapies.
New antitumor drugs have emerged for use in new treatment strategies, such as pazopanib and trabectedin (15, 16) . These drugs have been demonstrated to prolong the PFS, but they have also shown lower response rates. When considering new drugs for salvage chemotherapy, the CYVADIC regimen (a combination chemotherapy with a moderate response rate and a low rate of adverse events, especially cardiological) could be the treatment of choice for high risk patients with advanced STS originating from the non-extremities.
Conclusion
We herein described the prognoses of 30 patients with advanced STS of a non-extremity origin; their responses to CYVADIC therapy were moderate and essentially the same as those of previous studies, even though many patients with poor prognostic factors were among this population. We also discovered that the toxicity of the CYVADIC treatment was controllable, thus indicating that CYVADIC therapy could be a viable treatment option for patients with STS originating from a non-extremity site.
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